PF-05180999

DB14885InvestigationalSmall molecule

PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).

Mechanism: Pharmacologically active on cGMP-dependent 3',5'-cyclic phosphodiesterase
Curator reviewed
Formula / weight: C₁₉H₁₇F₃N₈ · 414.396 g/mol (avg)
Code names: PF-05180999

Resolves to

Compound

UNII5L84K4IEN9CAS1394033-54-5ChEMBLCHEMBL3092562

Structure

InChIKeyCLGCHUKGBICQTE-UHFFFAOYSA-NSMILESCN1N=CC(C2=C3N(N=CN=C3N3CCC3)C(C)=N2)=C1C1=NC=C(C=C1)C(F)(F)F

Targets

O00408PDE2A

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-05180999, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account